Retrogenix
Charles River Laboratories is dedicated to transforming possibilities into breakthroughs by bringing and sustaining vital drugs to market safely and efficiently. They are committed to accelerating the delivery of life-saving treatments, supporting scientific innovation, and operating responsibly with a focus on environmental, social, and governance (ESG) strategies. Their mission is to create healthier lives for patients, animals, and their people, emphasizing integrity, innovation, and community impact. The company actively invests in and embraces the 3Rs (Replacement, Reduction, Refinement) and the fourth R, Responsibility, to promote responsible animal research and scientific progress. They develop and implement new approach methods (NAMs), digital technologies, and innovative models to reduce animal use and enhance research quality. Charles River offers a broad portfolio of products and services across research models, drug discovery, safety assessment, and manufacturing, supporting clients from basic research to commercialization. The company engages in strategic partnerships with industry leaders to expand its capabilities in cell and gene therapy, in vitro models, digital pathology, and other advanced technologies. Recent initiatives include the development of animal-free endotoxin detection methods, virtual control groups, and high-throughput screening platforms. Charles River is committed to responsible science, animal welfare, and advancing innovative solutions that benefit patients, animals, and the environment.
Industries
Nr. of Employees
small (1-50)
Retrogenix
High Peak, Derbyshire, United Kingdom, Europe
Products
Secure study data and collaboration platform
A secure cloud platform for accessing, sharing and managing study-related information to improve data accessibility and accelerate decision making.
Cell microarray off-target screening platform
High-throughput cell microarray screening service to identify off-target interactions and provide specificity data suitable for regulatory submissions.
Recombinant animal-free endotoxin testing
Rapid animal-free recombinant endotoxin reagent testing method intended to replace traditional animal-derived assays in endotoxin detection workflows.
Real-time research model ordering platform
Digital ordering system for research animal models to enable real-time ordering and provisioning of model colonies and related services.
Virtual control group analytics
Analytical methods and software approaches that enable creation and use of virtual control groups to augment or reduce live control cohorts in preclinical studies.
Sentinel-free environmental sampling and pathogen detection service
A methodology combining environmental sampling with PCR-based assays for routine vivarium pathogen surveillance that reduces reliance on sentinel animals.
Secure study data and collaboration platform
A secure cloud platform for accessing, sharing and managing study-related information to improve data accessibility and accelerate decision making.
Cell microarray off-target screening platform
High-throughput cell microarray screening service to identify off-target interactions and provide specificity data suitable for regulatory submissions.
Recombinant animal-free endotoxin testing
Rapid animal-free recombinant endotoxin reagent testing method intended to replace traditional animal-derived assays in endotoxin detection workflows.
Real-time research model ordering platform
Digital ordering system for research animal models to enable real-time ordering and provisioning of model colonies and related services.
Virtual control group analytics
Analytical methods and software approaches that enable creation and use of virtual control groups to augment or reduce live control cohorts in preclinical studies.
Sentinel-free environmental sampling and pathogen detection service
A methodology combining environmental sampling with PCR-based assays for routine vivarium pathogen surveillance that reduces reliance on sentinel animals.
Services
Nonclinical study design and execution including inhalation, reproductive, carcinogenicity, safety pharmacology and GLP/non-GLP studies to support regulatory filings.
End-to-end development and GMP manufacturing for cell and gene therapies including process development, analytics and commercial-scale production.
Standardized tech-transfer frameworks, documentation and commercial-readiness risk mitigation services to accelerate cell therapy program scale-up.
Global testing and manufacturing services for biologics across discovery, preclinical, clinical and marketed product release.
Bioanalysis, biomarker assays, immunology, molecular biology, and clinical laboratory support for discovery through clinical phases.
Rapid microbial testing, identification, and endotoxin testing workflows for QC and production environments.
Nonclinical study design and execution including inhalation, reproductive, carcinogenicity, safety pharmacology and GLP/non-GLP studies to support regulatory filings.
End-to-end development and GMP manufacturing for cell and gene therapies including process development, analytics and commercial-scale production.
Standardized tech-transfer frameworks, documentation and commercial-readiness risk mitigation services to accelerate cell therapy program scale-up.
Global testing and manufacturing services for biologics across discovery, preclinical, clinical and marketed product release.
Bioanalysis, biomarker assays, immunology, molecular biology, and clinical laboratory support for discovery through clinical phases.
Rapid microbial testing, identification, and endotoxin testing workflows for QC and production environments.
Expertise Areas
- IND-enabling studies and regulatory submissions
- Preclinical toxicology and safety assessment
- Cell and gene therapy CDMO services and GMP manufacturing
- Tech transfer and commercial readiness for cell therapies
Key Technologies
- Next-generation sequencing (NGS)
- Quantitative PCR (qPCR)
- Organoids and 3D in vitro models
- Induced pluripotent stem cells (iPSC) and primary human cells
News & Updates
Webinar scheduled for August 13, 2025, online.
Webinar scheduled for August 20, 2025.
September 2-4, 2025 in Barcelona, Spain.
September 16-17, 2025 in Boston, MA.
October 30, 2025, online.
New Approach Methodologies for Drug Discovery and Development
Insights into innovative methods reducing animal testing and advancing alternatives.
Webinar scheduled for August 13, 2025, online.
Webinar scheduled for August 20, 2025.
September 2-4, 2025 in Barcelona, Spain.
September 16-17, 2025 in Boston, MA.
October 30, 2025, online.
New Approach Methodologies for Drug Discovery and Development
Insights into innovative methods reducing animal testing and advancing alternatives.